Why Moderna is laying off 10% of its workforce—and does RFK Jr. have anything to do with it?
Listen to this Article More info
0:00 / 3:30
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called 'a difficult decision but necessary step forward,' in an internal memo sent to employees today.
The move sent Moderna's stock price (NASDAQ: MRNA) tumbling over 5% through Thursday morning, and signals a further contraction of the once fast-growing business.
'I know this is a difficult moment for the company,' Bancel said in the memo announcing layoffs. 'We all feel a range of emotions whenever we have to say goodbye to colleagues.'
Moderna declined to comment on which areas of the business would be most impacted by the workforce reduction.
Moderna became a household name during the COVID-19 pandemic, when its mRNA vaccine became the second authorized for emergency use against COVID-19. At the time, it quickly scaled up its manufacturing capabilities and workforce to supply billions of vaccines in America and around the world.
Since the pandemic, however, the biotech firm has struggled to maintain the size of its operation. In 2024, Moderna's annual revenue was less than half of what it was in 2023—$3.2 billion compared to $6.8 billion.
This year, the company is seeing further decline. It brought in just $108 million in the first quarter, 35% less than the first quarter of 2024, as it faces mounting challenges from the federal government.
Under Robert F. Kennedy Jr., the new secretary of the Department of Health and Human Services (HHS) and proponent of the anti-vaxxer movement, the HHS has taken aim at the mRNA vaccines Moderna specializes in.
These vaccines work by introducing a piece of mRNA, a single-stranded molecule similar to DNA, that instructs cells on how to make a harmless version of a virus. The body then makes antibodies, proteins used by the immune system to annihilate harmful substances, that can fight off the real virus.
Although mRNA vaccines are widely used, safe, and effective, those skeptical of the innovation have driven lawmakers to curtail the companies behind them. In May, the CDC revised its guidelines for COVID-19 vaccination and the FDA made it more difficult for vaccines to be approved.
The second Trump administration also cancelled a $766 million contract with Moderna to develop a vaccine against influenza viruses, such as H5N1 bird flu—even as the company announced positive early results.
In response to uncertainty in the vaccine market and decreasing revenue, earlier this year, the company committed itself to reducing annual operating costs by $1.5 billion by 2027. The layoffs today are the next step in achieving that reduction, following a significant drop in R&D spending and limiting supplier and manufacturing costs.
Despite slimming down the business, Bancel said the company's mission will remain unchanged and notes there are still opportunities to expand Moderna's product line.
'The future of Moderna is bright,' Bancel said in a memo to employees. 'We are sharpening our focus, becoming leaner, and staying ambitious in oncology, rare diseases, and latent viruses.'
Moderna is expected to report its Q2 financial results tomorrow.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
a minute ago
- Chicago Tribune
Wall Street drifts around its records following a worldwide rally
NEW YORK — U.S. stocks are drifting around their record levels on Wednesday after a rally spurred by hopes for lower U.S. interest rates wrapped around the world. The S&P 500 was mostly unchanged, coming off its latest all-time high. The Dow Jones Industrial Average was up 285 points, or 0.6%, as of 1:19 p.m. Eastern time, while the Nasdaq composite was mostly unchanged after setting its own record the day before. Treasury yields eased in the bond market as expectations reached a virtual consensus that the Federal Reserve will cut its main interest rates for the first time this year at its next meeting in September. Lower rates can boost investment prices and the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment, though they risk worsening inflation. Stock indexes jumped in Asia in their first trading after Tuesday's better-than-expected report on U.S. inflation triggered a jump in bets that a cut to interest rates is coming. Hong Kong's Hang Seng leaped 2.6%, Japan's Nikkei 225 rallied 1.3% and South Korea's Kospi climbed 1.1%. Indexes also rose in Europe, though the moves were more modest after they already had the chance to trade on the U.S. inflation data the afternoon before. Germany's DAX returned 0.7%, and France's CAC 40 rose 0.7%. On Wall Street, the hopes for lower interest rates are helping to drown out criticism that the U.S. stock market has grown too expensive after its big leap since hitting a low in April. One way companies can make their stock prices look less expensive is to deliver strong growth in profits, and Brinker International became the latest to report stronger results for the latest quarter than analysts expected. The company behind the Chili's brand said it saw more customers coming to its restaurants, and it's also making more profit off each $1 in sales. 'Chili's is officially back, baby back!' said CEO Kevin Hochman. Its stock came into the day with a gain of 17.1% for the year so far, and it swung between gains and losses through the morning. It was most recently up 2.7%. HanesBrands climbed 4.2% after it agreed to sell itself to Gildan Activewear for $2.2 billion in cash and Gildan stock. The deal would combine North Carolinas' HanesBrands with Canada's Gildan, and Gildan's stock that trades in the United States rose 10.7%. Cryptocurrency exchange Bullish, which also owns crypto news site CoinDesk, surged in its debut on Wall Street. The stock nearly tripled from its $37 initial public offering price shortly after it started trading. On the losing end of Wall Street were grocery stores and delivery companies, which fell after Amazon said it will offer fresh groceries to customers in more than 1,000 cities and towns through same-day delivery. Kroger fell 4.2%, and DoorDash dropped 4.7%, while Amazon rose 1.3%. Cava Group sank 15.2% after the Mediterranean restaurant chain reported weaker revenue for the latest quarter than analysts expected, though its profit topped forecasts. It also cut its forecast for 2025 growth in sales at restaurants that have been open for more than a year, where guest traffic has been roughly flat recently from year-ago levels. CoreWeave lost 18.5% after the company, whose cloud platform helps customers running artificial-intelligence workloads, reported a larger loss for the latest quarter than analysts expected. In the bond market, Treasury yields eased as expectations built for coming cuts to interest rates by the Fed. The yield on the 10-year Treasury fell to 4.23% from 4.29% late Tuesday and from 4.50% in mid-July. That's a notable move for the bond market. President Donald Trump has angrily been calling for cuts to help the economy, often insulting the Fed's chair personally while doing so. But the Fed has been hesitant so far because of the possibility that Trump's tariffs could make inflation much worse. Lowering rates would give inflation more fuel, potentially adding oxygen to a growing fire. That's why Fed officials have said they wanted to see more data come in about inflation before moving. On Thursday, a report will show how bad inflation was at the wholesale level across the United States. Economists expect it to show inflation accelerated a touch to 2.4% in July from 2.3% in June.
Medscape
a minute ago
- Medscape
New Tools for Lung Cancer, Harder Job for Clinicians
This transcript has been edited for clarity. Hello. It's Mark Kris, from Memorial Sloan Kettering, with a month-later review of the 2025 ASCO meeting in Chicago. I think everybody who was there and attended the lung cancer sessions left with the, I'll have to say, difficult time unpacking what we learned during that meeting. There was a dizzying array of trials presented and a huge amount of data, but sadly, there was no breakthrough. There was no one treatment or approach that told each of us we had to start doing this in every patient on Tuesday when we got home again. What it did was give us more tools and more ways we could fight cancers, but it really made our jobs much harder. I think that we need to spend some time thinking about how those data could be used, and I'll pick a couple of examples. I think one would be in the small cell lung cancer area. There was a large amount of attention to the use of tarlatamab as a treatment at relapse. It was a comparison trial to topotecan and lurbinectedin, and there was an improvement in outcomes in those groups. While that benefit was there, what was not addressed was the benefit of repeating standard therapy, which is what many of us do, particularly when there has been a longer time between the end of the induction treatment and recurrence. The second trial that I thought was useful in the small cell area was a randomized trial adding lurbinectedin to the checkpoint inhibitor after induction chemotherapy. There was an improvement in disease-free survival there also. Personally, I was more impressed by the latter trial, in that it gave our patients a longer time with disease control rather than focusing the time of relapse, where people may already have suffered symptoms brought on by the progressive lung cancer — which sadly is an all-too-common occurrence. In the perioperative space, my colleague Jamie Chaft reported on neoadjuvant osimertinib. In her trial of osimertinib alone, osimertinib plus chemotherapy, and osimertinib and chemotherapy alone, they showed a benefit for the osimertinib-containing arms but not a clear benefit of osimertinib alone versus osimertinib plus chemotherapy. What's the take-home message there? Well, again, it's not simple. I think that we need to give chemotherapy to every patient with stage IB disease and beyond, whether they have an EGFR mutation or not. Based on the fact that we can give chemotherapy more safelyand more completely in the neoadjuvant setting, I would tend to use osimertinib with chemotherapy upfront and then surgery. If you do go the other way and use osimertinib alone, you would need to give chemotherapy afterward, which is, frankly, tougher. I think my take-home message from that was osimertinib and chemotherapy, our standard of care for advanced disease, should also be our standard for neoadjuvant disease in patients with EGFR mutations. There was a fantastic lecture by Patricia LoRusso, from Yale, about antibody-drug conjugates (ADCs). I think that was the most confusing moment of all during the ASCO meeting — the number of ADCs under evaluation. Yet, as Dr LoRusso pointed out, despite the number, it's the same targets, largely the same warheads, and very often, antibodies without activity in and of themselves. When you look at the overall benefits of the group, there are none that truly stand out. We now have three available in the lung cancer arena. The benefit, side effects, and the whole field is really quite confusing. One other message was that, with the bispecific antibodies, the more targets you have, the more toxicity you're going to see. It's a real balance between benefit and risk. What are you going to do? Again, there was no breakthrough at ASCO this year. Clearly, there are more therapies and there are even more in the pipeline. I think what we need to do now is to learn more, and to — unfortunately — spend a large amount of time going through the data and see exactly the benefit versus risk ratio for each of the new therapies and for each of our patients deciding where that goes. For example, I would be a big fan of giving lurbinectedin because of its ability to improve disease-free survival, which is so important in small cell [lung cancer], where relapse is almost certain, and that disease-free time is the best time for our patients. For the neoadjuvant, it would be giving both chemotherapy and osimertinibpre-surgery, in that is better tolerated there and you can also assess benefit very well. For tarlatamab, it's a tough decision there. Again, it's the time of relapse. We have many choices at relapse, giving the same drugs again, giving another perhaps less toxic agent like temozolomide, giving tarlatamab and the standard drugs. Clearly, tarlatamab was better than some of the standard drugs, but they're not the ones that most of us use for the patients. We usually go with the same treatment by and large. Lastly, it's going to be incumbent on us to work harder to take that information we got at ASCO this year and make the best decisions for each patient. We have to focus on the nuance. We have to learn more, and there is no knee-jerk that every patient needs tarlatamab or every patient should get induction chemotherapy with the combination. We have to choose our patients wisely. You've heard me before, and I'll say it again. Our jobs are better, but they're harder.
CNET
a minute ago
- CNET
Trying Not to Melt During Summer Heat Waves? Check Out These 9 Cooling Products
Summer heat is no joke, and 2025 has delivered massive heat waves that broke records across the US. If you're trying to enjoy the sun without melting in the process, you'll want to invest in a few items to keep you cool. Here are nine items you can use to survive this year's heat waves and summer highs. 1. Cooling towels A handheld towel is excellent for drying off after exercising, playing sports or doing hard work under the sun. A cooling towel is a step above. Just get these towels wet with cold water and wring out the extra water. Then, wrap the cooling towel around your neck or dab your face; it should stay cool for up to 2 hours. When it starts to warm up again, just add more water and repeat the process. These towels are great for a hot, summertime walk, relaxing at the beach or a long hike up the mountains. Mission Mission Cool Anywhere Towels These reusable, two-pack microfiber towels come in two different colors. They also offer UPF 50 sun protection. $23 at Mission 2. Electrolyte powder When you spend lots of time in the heat, your body actively loses water and electrolytes -- minerals found in the body that have a charge -- through sweat. It's important to replace that lost water and electrolytes with fluids. If you struggle to drink eight cups of water a day in the summer (and sometimes you need more if you're extremely active in the heat), an electrolyte drink can help replenish your body. The best electrolyte powders usually contain sodium, calcium, potassium, phosphate, chloride or magnesium. Electrolytes such as these can balance your body's water and pH levels, move nutrients throughout your cells, carry out waste from your cells, and ensure all muscles, bodily functions and nerves are working correctly. Amazon/Screenshot by CNET Liquid I.V. Hydration Multiplier Liquid I.V. powder provides two times faster hydration than water alone. It includes five vitamins and and many electrolytes. One bag of Liquid I.V. includes 16 on-the-go packets. Add one packet to 16 ounces of water and stir. $23 at Amazon 3. Reusable water bottle Rule No. 1 for surviving the heat: drink lots of water. Whether this is water or an electrolyte drink, hydration in the summer is key. You don't want to become dehydrated. Dehydration symptoms include tired, dark yellow urine, sunken eyes, headache and lightheadedness. I find that I drink the most water when I carry a water bottle around with me. I also drink more water when it stays ice cold throughout the day. An insulated stainless steel water bottle will do just that. Amazon/Screenshot by CNET Hydro Flask Choose between an 18-, 21- or 24-ounce Hydro Flask. Made with Pro-Made stainless steel, this water bottle is non-free, BPA-free and keeps water cold for up to 24 hours. $45 at Amazon 4. Portable fan A portable fan is handy when you miss the indoors or are dealing with broken AC. Cool down while walking, traveling or doing anything in the sun. It can even be useful for summer camping or hanging at the beach. Look for a portable fan that is easily rechargeable. Some fans can even mist your face. Amazon/Screenshot by CNET JISULIFE Handheld Mini Fan This chargeable, handheld fan is also a flashlight and a portable charger. Speed one can last up to 21 hours between charging and speed two can last up to 14 hours. $13 at Amazon 5. Sunscreen If you want to beat the heat, you first need to make sure your skin is protected. Wearing sunscreen should always be a priority if you're doing anything outside this summer. In addition to wearing sunglasses, a hat or UV protective clothing, sunscreen provides a shield to your delicate skin. Sunscreen provides protection from sun cancer, signs of sun damage and premature aging. You can try chemical, mineral or combo sunscreen. If you want a sunscreen that won't leave a white cast, look for a product with a light serum. If you have acne-prone skin, use a sensitive mineral or combo sunscreen. Amazon/Screenshot by CNET Neutrogena Mineral UltraSheer Dry-Touch Sunscreen Neutrogena Mineral UltraSheer Dry-Touch is lightweight, clean and contains SPF 30. It is water-resistant for up to 80 minutes. $9 at Amazon 6. Countertop ice machine There is nothing better than an ice-cold drink on a hot day. A countertop ice machine can bring the ice directly to you. You can add ice to your water or store beverages and take them with you; a countertop ice machine can be transported from one place to another. Take it camping orbring it to an outdoor party. You can have cold ice handy as long as you have access to an outlet. Amazon/Screenshot by CNET Igloo Portable Electric Countertop Ice Maker This Igloo ice maker can make ice in two different sizes. Just add water, select your ice size and ice will be ready in 7 minutes. There are multiple self-cleaning settings. $95 at Amazon 7. Cooling pillow When sleeping cool, using a fan, AC or light pajamas might be your go-to solution. However, changing your bedding is another easy fix. A cooling pillow is designed not to retain any body heat and to provide as much breathability as possible. Some cooling pillows even have a cool-to-the-touch cover. Pillows made of materials such as non-perforated and non-gel memory foam trap heat and will only make you hotter at night. Look for cooling pillows made of latex, foam, silk, cotton or bamboo. Note that the pillowcase you use may affect the cooling sensation of any pillow. I recommend looking for a silk, satin or light cotton pillowcase to accompany your cooling pillow. 8. Neck fan Why hold a fan in front of your face when one can sit on your neck? If you're working outside or have your hands full, a neck fan is practical. Shaped like headphones, neck fans wrap around the neck and both sides blow up toward the sides of your face and back of your neck. It's perfect for sitting inside without AC or working under the sun. Amazon/Screenshot by CNET ASNUG Neck Fan The ASNUG Neck Fan is blade-less, meaning that it won't snag hair, fingers or clothing. It has three settings and is rechargable via USB. $24 at Amazon 9. Cold facial mask A fun way to cool down is to use a cold facial mask. While I don't recommend wearing this outside, a cold compress can help calm hot, sweaty skin and bring down your internal temperature after being outside in the sun. Similar to cold rollers or certain eye creams, a cold face mask can even help depuff eyes. And if you are prone to migraines, a cold facial mask can aid a pounding headache.
